Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
Clinical trial NCT03598608 · TERMINATED
Trial details
- NCT number
- NCT03598608
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-17
- Primary completion
- 2026-01-28
- Enrollment
- 137
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.